市场调查报告书
商品编码
1497639
单采设备市场:按产品、程序、技术和应用 - 全球预测 2024-2030Apheresis Equipment Market by Product (Apheresis Machine, Disposable Apheresis Kits), Procedure (Erythrocytapheresis, LDL-Apheresis, Leukapheresis), Technology, Application - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年单采设备市场规模为29亿美元,预计2024年将达31.5亿美元,2030年将达53.2亿美元,复合年增长率为9.06%。
单采设备是医疗设备,单采是一种医疗程序,从患者或捐赠者身上取出全血,将其分离成单独的成分,保留这些成分中的一种或多种,并将剩余部分返回给患者或捐赠者。分离过程可以分离回收血浆(血液的液体部分)、血小板(帮助血液凝固的细胞)、红血球和白血球等成分。癌症和自体免疫疾病等需要血液成分治疗的疾病的发生率不断增加,推动了对单采术的需求。单采设备的创新使程序更加高效和安全,也推动了市场的成长。人们对各种疾病的单采疗法的可用性的认识不断提高也推动了市场的扩张。然而,缺乏对血浆分离术治疗益处的认识可能会阻碍市场成长。新设备核准的严格监管要求可能会延迟产品上市并增加市场开拓成本,对市场成长构成挑战。此外,自动化和整合系统等单采技术的创新提供了占领新细分市场的潜力。新兴国家医疗保健投资的增加是市场扩张的重大机会。
主要市场统计 | |
---|---|
基准年[2023] | 29亿美元 |
预测年份 [2024] | 31.5亿美元 |
预测年份 [2030] | 53.2亿美元 |
复合年增长率(%) | 9.06% |
区域洞察
由于发达的医疗基础设施、较高的捐血意识以及需要血浆和其他血液成分进行治疗的疾病的流行,美洲(尤其是美国和加拿大)对单采设备的需求很高。最近的投资旨在提高单采程序的效率和安全性,美洲地区的多项专利旨在最大限度地降低污染风险并改善自动化分离过程。欧洲国家对捐血和血液处理有严格的规定,并且注重医疗保健研发,单采血液的需求旺盛。中东和非洲地区的单采设备呈现多样化的格局,一些国家迅速发展医疗基础设施,为该地区的市场成长做出了贡献。亚太地区对单采设备的需求正在显着成长,特别是在中国、日本和印度。医疗保健成本不断上升、人们对捐血重要性的认识不断提高以及慢性病患病率不断上升,推动了亚太地区单采设备的迅速采用。在日本,技术先进的设备是首选,而在中国和印度,由于人口众多,成本效益和扩充性很重要。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在单采设备市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对单采设备市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外,该分析还提供了对该行业竞争性质的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在单采设备市场中的地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[193 Pages Report] The Apheresis Equipment Market size was estimated at USD 2.90 billion in 2023 and expected to reach USD 3.15 billion in 2024, at a CAGR 9.06% to reach USD 5.32 billion by 2030.
Apheresis equipment refers to medical devices used in apheresis, a medical procedure that involves removing whole blood from a patient or donor, separating it into individual components, and retaining one or more of these components while the rest are returned to the patient or donor. The separation process can isolate and collect components such as plasma (the liquid part of the blood), platelets (cells that help blood to clot), red blood cells, and white blood cells. Increased incidence of conditions that require blood component therapies, such as cancer and autoimmune diseases, drives demand for apheresis procedures. Technological innovations in apheresis equipment, making procedures more efficient and safe, also fuel market growth. Enhanced awareness regarding the availability of apheresis treatments for various conditions supports market expansion. However, a lack of awareness about the benefits of apheresis treatments may hinder market growth. Stringent regulatory requirements for approval of new devices may delay product launches and increase development costs, creating challenges for market growth. Moreover, innovation in apheresis technologies, such as automation and integrated systems, offers the potential for capturing new market segments. Increasing healthcare investments in emerging economies present significant opportunities for market expansion.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.90 billion |
Estimated Year [2024] | USD 3.15 billion |
Forecast Year [2030] | USD 5.32 billion |
CAGR (%) | 9.06% |
Regional Insights
In the Americas, with a particular focus on the United States and Canada, there is a high demand for apheresis equipment due to the developed healthcare infrastructure, high awareness levels about blood donation, and the prevalence of diseases requiring plasma and other blood components for treatment. Recent investments have been directed toward enhancing the efficiency and safety of apheresis procedures, with several patents filed in the Americas region, aiming to minimize contamination risks and improve automated separation processes. European countries exhibit robust demand for apheresis equipment, driven by strict regulations pertaining to blood donation and handling, as well as a strong focus on healthcare research and development. The Middle East and Africa region presents a varied landscape for apheresis equipment, with certain countries rapidly developing their healthcare infrastructure, contributing to the market growth in the region. The APAC region, particularly China, Japan, and India, is witnessing substantial growth in demand for apheresis equipment. The surge in adoption of apheresis equipment in the APAC region is propelled by increasing healthcare expenditure, rising awareness about the importance of blood donation, and a growing prevalence of chronic diseases. In Japan, the market is characterized by a preference for technologically advanced equipment, while in China and India, there's a focus on cost-effectiveness and scalability to meet the large population's needs.
Market Insights
The market dynamics represent an ever-changing landscape of the Apheresis Equipment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Apheresis Equipment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Apheresis Equipment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Enhancing Sickle Cell Treatment in England, A GBP 1.5 Million Investment in Advanced Apheresis Technology
In a significant development aimed at improving healthcare services for sickle cell disease patients in England, NHS England has announced a GBP 1.5 million (USD 1.8 million) investment to acquire 25 Spectra Optia Apheresis System devices. The automated red blood cell exchange offered by the Spectra Optia device aims to minimize these transfusions and also to manage pain more effectively and reduce the risk of crises. [Published On: 2024-02-14]
Revolutionizing Cell & Gene Therapy, A Transformative Partnership between Be The Match BioTherapies and Cryoport
Be The Match BioTherapies and Cryoport have embarked on a strategic alliance that greatly enhances the capabilities of IntegriCell, an integrated bioprocessing, cryopreservation, and distribution platform catering to the global cell therapy sector. This groundbreaking collaboration aims to streamline the entire bioprocessing and cryopreservation journey-spanning from the U.S. to Europe-by merging Be The Match BioTherapies' expertise in donor management and high-quality material collection with Cryoport's advanced cryopreservation, bioprocessing, and global logistics solutions. [Published On: 2023-10-09]
Sanguine Biosciences Opens Innovative Blood Donor Center for Enhanced Biomedical Research
Sanguine Biosciences has launched a cutting-edge blood donor center in Los Angeles, California, marking a significant milestone in precision medicine research and development. This facility is dedicated to the collection of concentrated white blood cell biospecimens, also known as leukopaks, from its extensive Patient Community network. This development underscores Sanguine's ambition to be at the forefront of providing valuable translational biospecimens to the biomedical research sector, leveraging its powerful patient engagement strategies and robust procurement capabilities. [Published On: 2023-09-13]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Apheresis Equipment Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Apheresis Equipment Market, highlighting leading vendors and their innovative profiles. These include Aikang Diagnostics Co., Ltd., Asahi Kasei Kuraray Medical Co. Ltd., B. Braun Melsungen AG, Bioelettronica S.r.l., Braun & Co. Limited, Cerus Corporation, Charles River Laboratories International, Inc., Cytosorbents Corporation, Delcon S.r.l., Fresenius Kabi AG, Haemonetics Corporation, Isto Biologics, JMS North America Corporation, Kaneka Corporation, LMB Technologie GmbH, Maco Pharma SAS, Mallinckrodt Pharmaceuticals Ireland Limited, MEDICA S.P.A., Medicap Clinic GmbH, Micro Technologies, Miltenyi Biotec B.V. & Co. KG, Nikkiso Co., Ltd., SB-Kawasumi Laboratories, Inc., and Terumo BCT Inc..
Market Segmentation & Coverage